EPIGEN COMPLETES BREAST CANCER MONITORING 'COD-TEST'
WELLESLEY, Mass., March 22 /PRNewswire/ -- Epigen, Inc. (AMEX-ECM: EPN.EC), a biopharmaceutical company developing monitoring aids and therapeutics for cancer patients, announced today that -- after eight years of research and development -- it has successfully completed the development of its first product, the "COD Test." The COD Test is an in vitro (outside the body) blood test which determines if a breast cancer patient is being treated successfully, and once the cancer is in remission, whether or not there are recurrences. There is no approved monitoring aid presently available for breast cancer patients in the United States. The COD Test measures nanogram (billionth of a gram) levels of HCA, an antigen that appears on the surface of tumors. There is a correlation between tumor burden and the amount of HCA antigen found in the bloodstream. Clinical trials of the new product will begin in April. Epigen said discussions are proceeding with potential strategic partners for the COD Test in the U.S., Europe and Asia. -0- 3/22/94 /CONTACT: James F. Mongiardo, President of Epigen, 617-237-9102 or Fax 617-237-7458/ (EPN.EC)
CO: Epigen, Inc. ST: Massachusetts IN: MTC SU: PDT
LD-SP -- NY003 -- 2353 03/22/94 08:50 EST
|Printer friendly Cite/link Email Feedback|
|Date:||Mar 22, 1994|
|Previous Article:||COUNTRYWIDE CREDIT'S FOURTH QUARTER EARNINGS RISE 21 PERCENT, BOARD DECLARES $0.12 CASH DIVIDEND AND 3-FOR-2 STOCK SPLIT|
|Next Article:||FORSCHNER APPOINTS THOMAS CUNNINGHAM EXECUTIVE VICE PRESIDENT AND CFO|